One of the major challenges to implementing personalized medicine is the lack of information about the risks and benefits of targeted drugs that are used off-label to treat patients whose tumor harbors a genomic abnormality.
Richard L. Schilsky, MD, FACP, FASCO
Response rate is not just a surrogate measure, it is a real-world clinical tool for patient assessment. Significant and prolonged reduction of tumor burden is clinically meaningful and could be used for regulatory approval.
Gideon Blumenthal, MD
Forum participants agreed that:
In an oncology health-care system that is increasingly changing its delivery and payment models, how do busy oncologists successfully bridge the transition from a volume- to value-based, patient-centric model? This, and other topics on value fueled a robust discussion at the Association of...